Accreditation and regulatory mandates for laboratory quality control are the largest single contributor to growth in the in vitro diagnostics (IVD) quality control market, and the study rates their impact high. Laboratories must show, run after run, that an instrument, reagent and assay combination returns accurate and reproducible results before a patient sample is reported. Every requirement to document that performance means more control material purchased, more software to log the outcomes and more external verification of the laboratory's work.
Contrive Datum Insights has published "In Vitro Diagnostics Ivd Quality Control Market Size, Share & Industry Analysis, By Type (Other, Quality Assurance Services, Data Management), Application (Clinical Chemistry, Hematology, Immunoassay, Molecular Diagnostics, Microbiology, Coagulation/Hemostasis, Others), End-user (Hospitals, Clinical/Reference Laboratories, Research and Academic Institutes, Others), Control source (Instrument-Specific (OEM) Controls, Third-Party/Independent Controls), Distribution channel (Direct Sales, Third-Party Distributors), and Regional Forecast, 2026-2034". The study sizes the global market at USD 1.52 billion in 2025 and projects growth from USD 1.62 billion in 2026 to USD 2.59 billion by 2034, a compound annual growth rate of 6.04% across the forecast period.
The study covers five axes, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with country-level detail for all five regions, the competitive landscape and the research methodology. It is delivered as a PDF, and a free sample is available on request.
The segment that gains most from the mandate is Data Management. Tracking control results against acceptable ranges is the work an accreditor asks to see, and this line compounds at 8.67%, lifting its share of revenue from 21.7% to 27% and its value from USD 0.33 billion to USD 0.7 billion. The category labeled Other remains much larger, holding 45.4% of 2025 revenue at USD 0.69 billion and still leading in 2034 at 40.9%. Elsewhere, Molecular Diagnostics is the fastest application at 13.53%, though Clinical Chemistry is the biggest in 2025 at 30.3% of revenue. Instrument-Specific (OEM) Controls account for 57.9% of 2025 revenue, while Third-Party/Independent Controls grow faster at 7.43%. Direct Sales carry 63.8% of the market today, and Clinical/Reference Laboratories are the largest end-user group at 42.1%.
Revenue is concentrated in North America, with 36.8% of 2025 global revenue, USD 0.56 billion rising to USD 0.88 billion in 2034. The United States alone is the largest country market at USD 0.48 billion, or 31.6% of the global total. Asia Pacific is the region gaining ground, moving from 23.7% of revenue to 27% over the period as its value grows from USD 0.36 billion to USD 0.7 billion. Middle East and Africa remains the smallest contributor, at 5.3% in 2025 and 6.2% in 2034.
The forecast has a range around it. In the bull case, accreditation mandates tighten faster than planned across mid-income markets and molecular diagnostics QC adoption outpaces the base forecast, taking 2034 revenue to USD 2.82 billion. The bear case is more specific. Laboratory group purchasing intensifies pricing pressure, and public healthcare budget constraints delay QC program expansion in several forecast markets, leaving 2034 revenue at USD 2.36 billion. Quality Assurance Services is the drag in that outcome: it makes up 32.9% of the 2025 base and compounds at 5.77% while the market as a whole runs at 6.04%.